Opinion: Proposed cuts could have ‘catastrophic effect,’ 110 biomedical, health sciences industry leaders tell Congress
Proposed cuts will have “a catastrophic effect on the advancement of biomedical and biotechnology capabilities in the United States,” more than 100 leaders of biomedical/health sciences companies tell Congress.
As leaders of United States companies positioned in the biomedical/health sciences landscape, we are well aware that our companies are but one component of an expansive and interconnected scientific ecosystem requiring federal, industry, and academic partnership.
Government funding of research and industry work in the life sciences plays a critical role in this ecosystem, creating a cycle of innovation and economic growth that improves the health and well-being of the nation’s citizens and helps to ensure that the United States leads in critical areas such as therapeutic development, advanced biomanufacturing, AI-informed technologies, and more.
